These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 39042154)

  • 1. Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis.
    Guan R; Lin Y; Zhang C; Wang Z; Wu Z; Liu X; Chen X; Piao Y
    Arch Dermatol Res; 2024 Jul; 316(7):483. PubMed ID: 39042154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploring Janus kinase inhibitors for alopecia areata: a comprehensive review.
    Bushwereb R; Srivastava G
    Ital J Dermatol Venerol; 2024 Aug; 159(4):380-389. PubMed ID: 38780910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of moderate-to-severe alopecia areata in patients over the age of 65 years with baricitinib.
    Tang GT; Triwongwaranat D; Sinclair R; Joseph S; Eisman S; Rathnayake D; Varathan V; Trindade de Carvalho L; Bhoyrul B
    Clin Exp Dermatol; 2024 Jul; 49(8):875-878. PubMed ID: 38270233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two Phase 3 Trials of Baricitinib for Alopecia Areata.
    King B; Ohyama M; Kwon O; Zlotogorski A; Ko J; Mesinkovska NA; Hordinsky M; Dutronc Y; Wu WS; McCollam J; Chiasserini C; Yu G; Stanley S; Holzwarth K; DeLozier AM; Sinclair R;
    N Engl J Med; 2022 May; 386(18):1687-1699. PubMed ID: 35334197
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatments for alopecia areata: a network meta-analysis.
    Mateos-Haro M; Novoa-Candia M; Sánchez Vanegas G; Correa-Pérez A; Gaetano Gil A; Fernández-García S; Ortega-Quijano D; Urueña Rodriguez MG; Saceda-Corralo D; Bennouna-Dalero T; Giraldo L; Tomlinson J; Vaño-Galván S; Zamora J
    Cochrane Database Syst Rev; 2023 Oct; 10(10):CD013719. PubMed ID: 37870096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
    Wei D; Chen Y; Shen Y; Xie B; Song X
    Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
    Song CJ; Riley CA; Wilkison BD; Cho S
    Mil Med; 2024 Jun; ():. PubMed ID: 38850223
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ritlecitinib: an investigational drug for the treatment of moderate to severe alopecia areata.
    Eisman S; Sinclair R
    Expert Opin Investig Drugs; 2021 Dec; 30(12):1169-1174. PubMed ID: 34826225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Oral Baricitinib Restores Hair Loss in Alopecia Areata.
    Slomski A
    JAMA; 2022 Jun; 327(24):2386. PubMed ID: 35762995
    [No Abstract]   [Full Text] [Related]  

  • 10. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
    Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
    King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
    J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results.
    King B; Guttman-Yassky E; Peeva E; Banerjee A; Sinclair R; Pavel AB; Zhu L; Cox LA; Craiglow B; Chen L; Banfield C; Page K; Zhang W; Vincent MS
    J Am Acad Dermatol; 2021 Aug; 85(2):379-387. PubMed ID: 33757798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy of oral Janus kinase inhibitors and biologics in adult alopecia areata: A systematic review and Bayesian network meta-analysis.
    Husein-ElAhmed H; Husein-ElAhmed S
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):835-843. PubMed ID: 38279559
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case report: Sequential therapy with dupilumab and baricitinib for severe alopecia areata with atopic dermatitis in children.
    Fang H; Zhang F; Lin W; Jiang Y; Liu Q; Yang D
    Front Immunol; 2024; 15():1395288. PubMed ID: 38903518
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
    Lee S; Kim BJ; Lee YB; Lee WS
    JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Review of Baricitinib in the Treatment of Alopecia Areata.
    Singh R; Driscoll MS
    J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase inhibitors: An innovative treatment for alopecia areata.
    Park H; Yu DA; Kwon O
    J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
    Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
    Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
    Durdu M; Özcan D; Baba M; Seçkin D
    J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.